|
Andreu JM, Roldán V, García-Navarro M, Ruipérez JA, Valdés M, Marín F. [Should we add antiplatelet therapy to oral anticoagulation in patients with atrial fibrillation and vascular disease? Review of available evidence]. Arch Cardiol Mex. 2012 Jul-Sep;82(3):248-51. doi: 10.1016/j.acmx.2012.03.002. Epub 2012 Sep 14. Spanish. PubMed PMID: 23021363.
AÑO: 2012; IF: 4.78
|
23021363
|
Roldán V, Marín F, Díaz J, Gallego P, Jover E, Romera M, Manzano-Fernández S, Casas T, Valdés M, Vicente V, Lip GY. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J Thromb Haemost. 2012 Aug;10(8):1500-7. doi: 10.1111/j.1538-7836.2012.04812.x. PubMed PMID: 22681487.
AÑO: 2012; IF: 6.081
|
|
Roldán Schilling V, Vicente García V. [Pharmacodynamic and pharmacokinetic characteristics. Mechanism of action of the new oral anticoagulants]. Med Clin (Barc). 2012 Oct;139 Suppl 2:10-2. doi: 10.1016/S0025-7753(12)70035-0. Review. Spanish. PubMed PMID: 23498066.
AÑO: 2012; IF: 1.399
|
|
Roldán V, Marín F. Oral anticoagulation in chronic kidney disease: A huge challenge. Thromb Haemost. 2012 Jul;108(1):3-5. doi: 10.1160/TH12-05-0324. Epub 2012 May 25. PubMed PMID: 22628077.
AÑO: 2012; IF: 6.094
|
|
Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M, Vicente V, Lip GY. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011 Jun 21;57(25):2496-504. doi: 10.1016/j.jacc.2010.12.033. Epub 2011 Apr 14. PubMed PMID: 21497043.
AÑO: 2011; IF: 14.156
|